Xtoro generics — when can they launch?
Xtoro (FINAFLOXACIN) · Fonseca Biosciences · 4 active US patents · 0 expired
Where Xtoro sits in the generic timeline
Mid-term cliff: earliest active US patent for Xtoro expires in 2030 (~4 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 3 patents
- Formulation — 1 patent
FDA U-codes carved out by Xtoro patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1679 | (no description) |
Sample patent estate
Showing 4 of 4 active US patents. View full estate on the Xtoro drug page →
-
This patent protects methods and compositions for treating ophthalmic, otic, or nasal infections using finafloxacin or a finafloxacin derivative.USPTO title: Compositions and methods for treating ophthalmic, octic, or nasal infections
-
This patent protects methods for treating ophthalmic, otic, or nasal infections using a composition containing finafloxacin or a finafloxacin derivative.USPTO title: Methods for treating otic infections
-
This patent protects methods for treating ophthalmic, otic, or nasal infections using a composition containing finafloxacin or a finafloxacin derivative.USPTO title: Methods for treating ophthalmic, otic, or nasal infections
-
This patent protects methods for treating ophthalmic, otic, or nasal infections using a suspension composition containing finafloxacin or a finafloxacin derivative.USPTO title: Finafloxacin suspension compositions
Sources
- FDA Orange Book — patents listed against Xtoro (NDA filed 2014)
- Xtoro drug profile — full patent estate, indications, clinical trials, pricing
- Fonseca Biosciences patent portfolio
- Patent cliff 2030 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Xtoro — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →